NCT07269912

Brief Summary

Rectal cancer (RC) is among the most prevalent gastrointestinal cancers \[1\], characterized by significant tumor heterogeneity \[2\]. Neoadjuvant chemoradiotherapy followed by total mesorectal excision is a standard treatment for locally advanced rectal cancer \[3\]. Although the locoregional recurrence rate has decreased due to this treatment, distant metachronous metastases still occur in over 20-30% of cases \[4,5\]. The varying biological characteristics of rectal cancer may result in different treatment responses and prognoses \[6\]. Patients who are diagnosed with the same tumor-node-metastasis (TNM) stage of RC frequently exhibit vastly different clinical outcomes, despite receiving the same therapeutic interventions \[7\]. While the TNM staging system remains the predominantly used framework for directing treatment choices and forecasting prognosis, it is crucial to take into account additional pathological elements, such as tumor budding, lymphovascular invasion (LVI), perineural invasion, and extramural venous invasion \[8-10\]. A recent investigation has highlighted that LVI, rather than the traditionally prioritized extent of tumor invasion, serves as a significant risk factor for metastasis in early-stage RC \[11\]. Patients exhibiting LVI+ demonstrate a considerably worse prognosis and overall survival when compared to those with LVI -. Identifying LVI before surgery is crucial for informing treatment strategies in RC \[12\]. LVI offers important information regarding the tumor's biological behavior and its likelihood of metastasizing, thus improving the precision of disease staging. This information enables clinicians to tailor treatment approaches, which helps prevent overtreatment in patients with LVI -. In cases where LVI is present, it may be essential to adopt more aggressive treatment methods, such as postoperative chemotherapy, radiotherapy, or more extensive surgical resections, to reduce the chances of recurrence and metastasis. In summary, LVI serves as a crucial prognostic factor, providing essential insights into the tumor's potential for metastasis and recurrence, which has significant clinical implications for predicting postoperative outcomes, including recurrence, metastasis, and disease-free survival. Therefore, a preoperative non-invasive assessment of LVI, particularly in patients with LVI +, may be instrumental in guiding clinical practice. Conventional magnetic resonance imaging (MRI) is particularly effective in observing large blood vessels and has moderate sensitivity and high specificity to distinguish LVI \[13\]. However, it can noninvasively and accurately assess extramural vascular invasion with a diameter greater than 3 mm. In contrast, it is challenging to evaluate vascular invasion with a diameter less than 3 mm, as well as intramural vascular and lymphatic infiltration, due to the limitations in resolution \[14,15\]. In addition, pathological biopsy is the gold standard for preoperative diagnosis. However, this invasive approach may not reflect the LVI status of the entire tumor due to possible sample errors \[16\]. Therefore, effectively assessing LVI in RC via preoperative imaging remains a significant challenge. Intravoxel incoherent motion (IVIM) is a functional imaging method that can display the diffuse movement of water molecules and blood flow, microcirculation perfusion, thereby improving the diagnostic accuracy of RC \[17,18\]. The IVIM model has the potential to identify perfusion effects using multiple b-value samples and biexponential curve fit analysis \[19\], which can lead to three parameters, namely the true diffusion coefficient (D), the pseudo-diffusion coefficient (D\*), and the perfusion fraction (f). Li et al \[20\]. discovered that the D value obtained from IVIM of LVI+ patients was significantly higher than that of LVI- patients with RC, but only 42 patients were included in this study, making it more difficult to accurately assess the feasibility of IVIM. In another study, Kan et al \[21\]. revealed that the D value was helpful to assess the prognostic factor related to RC, while the AUC of the D value for evaluating LVI was only 0.646. Currently, studies utilizing conventional IVIM quantitative parameters have demonstrated a relatively low diagnostic efficiency in detecting LVI, with AUC values ranging from 0.629 to 0.646 \[22,23\]. Tumor heterogeneity has emerged as a significant biomarker for tumor staging and prognosis \[24\]. Sub-region analysis, an innovative imaging post-processing technique, has demonstrated its potential in exploring intratumor heterogeneity in recent years. Prior research has underscored the importance of sub-region analysis derived from either single-modality or multiparametric MRI in the investigation of intratumor heterogeneity in RC \[25-27\]. However, to our knowledge, the application of sub-region analysis based on IVIM-MRI to evaluate LVI status and prognosis in patients with RC has not been reported. Thus, this study aimed to assess the fe

Trial Health

65
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
400

participants targeted

Target at P75+ for all trials

Timeline
0mo left

Started Nov 2027

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 26, 2025

Completed
12 days until next milestone

First Posted

Study publicly available on registry

December 8, 2025

Completed
1.9 years until next milestone

Study Start

First participant enrolled

November 1, 2027

Expected
Same day until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2027

Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2027

Last Updated

December 8, 2025

Status Verified

September 1, 2025

Enrollment Period

Same day

First QC Date

November 26, 2025

Last Update Submit

November 26, 2025

Conditions

Outcome Measures

Primary Outcomes (3)

  • "Number of Participants with Local Recurrence and Metastasisas Assessed by MRI"

    From enrollment to the end of treatment at 2 years

  • The time of local recurrence and metastasis was defined as the interval from surgery to the detection of local recurrence and/or metastasis. The primary endpoint of the study was a 2-year DFS.

    From enrollment to the end of treatment at 2 years

  • Number of Participants with local recurrence and metastasis as Assessed by digital rectal examinations, CEA level, endoscopic examinations, and CT or MRI scans of the head, chest, and abdominopelvic cavity

    From enrollment to the end of treatment at 2 years"

Interventions

intravoxel incoherent motion magnetic resonance imaging

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

400 patients diagnosed with rectal cancer from the sichuan cancer hospital were consecutively recruited in this study

You may qualify if:

  • (1) patients underwent preoperative abdominal pelvic IVIM-MRI examination; (2) patients underwent surgical resection within 2 weeks after IVIM-MRI examination; (3) complete postoperative pathological data, including LVI status.

You may not qualify if:

  • (1) radiotherapy or chemotherapy before surgery; (2) preoperative metastatic disease; (3) poor image quality; (4) incomplete clinical data.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Rectal Neoplasms

Condition Hierarchy (Ancestors)

Colorectal NeoplasmsIntestinal NeoplasmsGastrointestinal NeoplasmsDigestive System NeoplasmsNeoplasms by SiteNeoplasmsDigestive System DiseasesGastrointestinal DiseasesIntestinal DiseasesRectal Diseases

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Sub-region Analysis Based on Intravoxel Incoherent Motion MRI for Preoperative Prediction of Lymphovascular Invasion and Prognosis in Rectal Cancer

Study Record Dates

First Submitted

November 26, 2025

First Posted

December 8, 2025

Study Start (Estimated)

November 1, 2027

Primary Completion (Estimated)

November 1, 2027

Study Completion (Estimated)

November 1, 2027

Last Updated

December 8, 2025

Record last verified: 2025-09